Institute of Molecular Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, State Key Laboratory of Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Laboratory Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Nat Nanotechnol. 2020 Aug;15(8):709-715. doi: 10.1038/s41565-020-0699-0. Epub 2020 May 25.
Early and precise cancer diagnosis substantially improves patient survival. Recent work has revealed that the levels of multiple microRNAs in serum are informative as biomarkers for the diagnosis of cancers. Here, we designed a DNA molecular computation platform for the analysis of miRNA profiles in clinical serum samples. A computational classifier is first trained in silico using miRNA profiles from The Cancer Genome Atlas. This is followed by a computationally powerful but simple molecular implementation scheme using DNA, as well as an effective in situ amplification and transformation method for miRNA enrichment in serum without perturbing the original variety and quantity information. We successfully achieved rapid and accurate cancer diagnosis using clinical serum samples from 22 healthy people (8) and people with lung cancer (14) with an accuracy of 86.4%. We envision that this DNA computational platform will inspire more clinical applications towards inexpensive, non-invasive and rapid disease screening, classification and progress monitoring.
早期、准确的癌症诊断可显著提高患者的生存率。最近的研究表明,血清中多种 microRNA 的水平可作为癌症诊断的生物标志物。在这里,我们设计了一个用于分析临床血清样本中 microRNA 谱的 DNA 分子计算平台。首先使用来自癌症基因组图谱的 microRNA 谱在计算机上对计算分类器进行训练。然后,使用 DNA 进行计算能力强但简单的分子实现方案,以及一种有效的原位扩增和转化方法,在不干扰原始种类和数量信息的情况下富集血清中的 microRNA。我们使用来自 22 名健康人(8 名)和肺癌患者(14 名)的临床血清样本成功实现了快速、准确的癌症诊断,准确率为 86.4%。我们设想,这个 DNA 计算平台将激发更多的临床应用,以实现廉价、非侵入性和快速的疾病筛查、分类和进展监测。
Nat Nanotechnol. 2020-5-25
Biochim Biophys Acta Mol Basis Dis. 2020-5-27
Nature. 2025-9-3
J Nanobiotechnology. 2025-9-1
Sci Adv. 2025-8-22
Smart Mol. 2023-12-12
Adv Sci (Weinh). 2025-8
Sci Adv. 2025-5-2